SAFETY PROFILE OF THE IL-1 RECEPTOR ANTAGONIST KINERET® (ANAKINRA) IN A LONG-TERM OUTCOME STUDY IN PATIENTS WITH SEVERE CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)

被引：0
|
作者：
Kullenberg, T. [1 ]
Lofqvist, M. [1 ]
Olivecrona, H. [1 ]
Plass, N. [2 ]
Kost, B. [2 ]
Sibley, C. [2 ]
Goldbach-Mansky, R. [2 ]
机构：
[1] Swedish Orphan Biovitrum, Stockholm, Sweden
[2] NIAMSD, NIH, Bethesda, MD 20892 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：745 / 746
页数：2
相关论文
共 50 条
  • [1] Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes
    Kullenberg, Torbjorn
    Lofqvist, Malin
    Leinonen, Mika
    Goldbach-Mansky, Raphaela
    Olivecrona, Hans
    [J]. RHEUMATOLOGY, 2016, 55 (08) : 1499 - 1506
  • [2] THE IL-1RA ANTAGONIST KINERET® (ANAKINRA) STABILIZES HEARING LOSS IN PATIENTS WITH SEVERE CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)
    Leinonen, M.
    Soderberg, K.
    Olivecrona, H.
    Raboisson, M. Alden
    Sibley, C.
    Brewer, C.
    Plass, N.
    King, K.
    Zalewski, C.
    Kim, J.
    Stone, D.
    Chapelle, D.
    Goldbach-Mansky, R.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 730 - 731
  • [3] The IL-1 receptor antagonist anakinra (kineret®) stabilizes the NLRP3 mutation-specific risk for hearing loss in patients with severe cryopyrin-associated periodic syndromes (CAPS)
    Mika Leinonen
    Bengt Hallén
    Hans Olivecrona
    [J]. Pediatric Rheumatology, 12 (Suppl 1)
  • [4] The Effect of IL-1 Receptor Antagonist Anakinra (Kineret®) on Measures of Central Nervous System Inflammation and Headaches in Pediatric Patients with Severe Cryopyrin-Associated Periodic Syndromes
    Olivecrona, Hans
    Goldbach-Mansky, Raphaela
    Kullenberg, Torbjorn
    Leinonen, Mika
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [5] EFFECT OF LONG-TERM TREATMENT WITH ANAKINRA (KINERET®) ON BONE MINERAL DENSITY IN PATIENTS WITH SEVERE CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES
    Timdahl, K.
    Goldbach-Mansky, R.
    Leinonen, M.
    Olivecrona, H.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 386 - 386
  • [6] Long-term safety of rilonacept (IL-1 trap) in cryopyrin-associated periodic syndromes (CAPS): Results from a 1-year study
    Hoffman, H.
    Grimes, I
    Weinstein, S.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2008, 26 (02) : 205 - 206
  • [7] STEROID-SPARING EFFECT OF ANAKINRA (KINERET®) IN THE TREATMENT OF PATIENTS WITH SEVERE CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES
    Kullenberg, T.
    Hallen, B.
    Olivecrona, H.
    Leinonen, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 607 - 607
  • [8] Dose Adjustment of Anakinra (Kineret®) Based on Clinical Response in Patients with Severe Cryopyrin-Associated Periodic Syndromes
    Hallen, Bengt
    Kullenberg, Torbjorn
    Leinonen, Mika
    Wiken, Margareta
    Goldbach-Mansky, Raphaela
    Olivecrona, Hans
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [9] Rapid and Sustained Response in Patients Suffering From Severe Cryopyrin-Associated Periodic Syndromes Treated With Anakinra (Kineret®)
    Leinonen, Mika
    Hallen, Bengt
    Olivecrona, Hans
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S3 - S3
  • [10] Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL- 1 Trap)
    Church, Leigh D.
    Savic, Sinisa
    McDermott, Michael F.
    [J]. BIOLOGICS-TARGETS & THERAPY, 2008, 2 (04): : 733 - 742
12345